Metformin's contraindications should be contraindicated

CMAJ. Canadian Medical Association Journal

Volumn 173, Issue 5, 2005, Pages 502-504

  McCormack, James ^a,b   Johns, Kevin ^b   Tildesley, Hugh ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; INSULIN; METFORMIN;

AGE; AGED; ALCOHOL CONSUMPTION; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG CONTRAINDICATION; HUMAN; INCIDENCE; KIDNEY DYSFUNCTION; LACTIC ACIDOSIS; LIVER DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRACTICE GUIDELINE; PRESCRIPTION; RISK BENEFIT ANALYSIS; UNITED KINGDOM;

EID: 24044478791     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.045292     Document Type: Note

References (23)

1. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 1999;20:489-503.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
3. Stang M, Wysowski DK, Butler-Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care 1999;22:925-7.
4. Canadian Pharmacists Association. Compendium of pharmaceutical and specialties. Ottawa: The Association; 2001.
5. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med 2002;162:434-7.
6. McCormack J, Greenhalgh T. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. BMJ 2000;320: 1720-3.
7. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-MDDM trial. JAMA 2003;290:486-94.
8. Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C. [alpha]-Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154.
9. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-6.
10. Van de Laar FA, Lucassen PL. No evidence for a reduction of myocardial infarctions by acarbose [letter]. Eur Heart J 2004;25:1179.
11. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
12. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch Intern Med 2003;163:2594-602.
13. Brown JB, Pedula K, Barzilay J, Herson MK, Latare P. Lactic acidosis rates in type 2 diabetes. Diabetes Care 1998;21:1659-63.
14. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded. Diabet Med 1999;16:692-6.
15. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001; 18:483-8.
16. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, et al. Role of Metformin Accumulation in metformin-associated lactic acidosis. Diabetes Care 1995;18:779-84.
17. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997;20:925-8.
18. Waters AK, Morgan DB, Wales JK. Blood Lactate and pyruvate levels in diabetic patients treated with biguandes with and without sulphonylureas. Diabetologia 1978;14:95-8.
19. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gabbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998;338:265-6.
20. Ellis AK, Iliescu EA. Metformin-associated lactic acidosis in a low risk patient. Can J Clin Pharmacol 2001;8:104-6.
21. Khan JK, Muralidhar P, Tolber SR, Hornick TR. Lactic acidemia associated with metformin. Ann Pharmacother 2003;37:66-9.
22. Assan R, Heuclin C, Ganeval D, Bismuth C, George J, Richard JR. Metformin-induced lactic acidosis in the presence of acute renal failure. Diabetologia 1977;13:211-7.
23. Jones GC, Macklin JP, Alexander WD. Contraindications to the use of metformin. BMJ 2003;326:4-5.